Clinical trials: No Reflow
Coronary Arteriosclerosis, Coronary Heart Disease
Analysis of Human Coronary Aspirate
During elective percutaneous coronary intervention (PCI), both proximal and distal protection devices are used. The distal occlusion protection device temporarily occludes the vessel distal to the lesion during the intervention…
- Conditions
- Coronary Arteriosclerosis, Coronary Heart Disease, No Reflow Phenomenon
- Trial name
- AHCA (NCT01430884)
- Testing
- Aspirated Coronary Blood
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Universität Duisburg-Essen
Acute Cerebrovascular Accident, Thrombectomy
Investigation of Brain Blood Flow Changes in Acute Ischemic Stroke Patients After Successful Endovascular Thrombectomy
Introduction: Endovascular thrombectomy (EVT) is an effective treatment strategy to mitigate the ischemic tissue damage caused by the acute cerebral large-vessel occlusion.
- Conditions
- Acute Cerebrovascular Accident, Thrombectomy, Cerebral Revascularization, No Reflow Phenomenon
- Trial name
- RESTORE-AIS (NCT07534319)
- Testing
- No planned intervention
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Zurich
Acute ST-segment Elevation Myocardial Infarction
Effects of Glucagon Like Peptide-1 on No-reflow
The investigators planned to evaluate the effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction (STEMI).
- Trial name
- NCT02507128
- Testing
- liraglutide
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Chen Wei Ren, MD
STEMI, No-Reflow Phenomenon
Empagliflozin for No-reflow Phenomenon in PCI for STEMI
Myocardial infarction remains, in our current era, a leading cause of morbidity and mortality both domestically and globally. A significant contributor to this issue is reperfusion injury, which enlarges the infarction…
- Trial name
- EMPA-PCI (NCT06342141)
- Testing
- Empagliflozin 25 milgrams (Mg), Empagliflozin 10 Mg
- Where
- Mexico
- Volunteers
- 162 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Ischemia-reperfusion Injury, No-reflow
Intracoronary Administration of Glucocorticoids as a Treatment Method for No-Glucocorticoid Treatment for No-Reflow in STEMI
The goal of this clinical trial is to improve reperfusion therapy in STEMI patients with no-reflow phenomenon. Based on literature review and pathological studies, the investigators believe that myocardial ischemia-reperfusion…
- Trial name
- GCT-NR-STEMI (NCT06552442)
- Testing
- Methylprednisolone
- Where
- Ukraine
- Volunteers
- 10 people
- Sponsor
- Amosov National Institute of Cardiovascular Surgery
ST Elevation Myocardial Infarction (STEMI), Acute Coronary Syndromes (ACS)
A Single-Center, Retrospective, Propensity-Score-Matched Cohort Study Comparing Drug-Coated Balloon Versus Drug-Eluting Stent for Reducing Immediate Post-Procedural Slow-Flow/No-Reflow in Acute ST-Elevation Myocardial Infarction Patients With High Thrombus Burden
This is a single-center, retrospective, propensity-score-matched observational study. It aims to compare the rate of immediate slow-flow or no-reflow after percutaneous coronary intervention (PCI) between drug-coated balloon…
- Trial name
- STEMI-DCB (NCT07806370)
- Testing
- Drug-Coated Balloon (DCB), Drug-Eluting Stent (DES)
- Where
- China
- Volunteers
- 668 people
- Sponsor
- Xijing Hospital
Acute Coronary Syndrome, No-Reflow Phenomenon
Adrenaline for the Treatment of No-Reflow in Normotensive Patients
No-reflow is defined as the lack of myocardial perfusion despite opening of the epicardial coronary vessels in the setting of percutaneous coronary intervention (PCI).
- Conditions
- Acute Coronary Syndrome, No-Reflow Phenomenon, Normotensive
- Trial name
- NCT04699110
- Testing
- Adrenaline, Adenosine
- Where
- Pakistan
- Volunteers
- 201 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
No-Reflow Phenomenon, Coronary Artery Disease
A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease
The aim of this study was to determine the effect of intra-coronary administration of nicorandil on the prevention of lowering of coronary blood flow for high-risk plaque lesions defined as the high value of lipid core burden…
- Conditions
- No-Reflow Phenomenon, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- NCT05427786
- Testing
- Nicorandil
- Where
- South Korea
- Volunteers
- 458 people
- Sponsor
- Korea University Anam Hospital
Integrated Assessment, Immune-Inflammatory
Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following Primary PCI in STEMI Patients
This study aims to evaluate the combined predictive value of immune-inflammatory and metabolic biomarkers for coronary no-reflow following primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation…
- Conditions
- Integrated Assessment, Immune-Inflammatory, Metabolic Biomarkers, Coronary No-Reflow
- Trial name
- NCT07890168
- Testing
- Assessment of immune-inflammatory and metabolic biomarkers
- Where
- Egypt
- Volunteers
- 400 people
- Sponsor
- Sohag University
ST Segment Elevation Myocardial Infarction (STEMI), No Reflow Phenomenon
The Investigator Administers Intracoronary Adrenaline Via the Catheter in STEMI Patients During Primary PCI, After Flow Restoration and Before Stenting, and Studies Its Effect in Prevention of No Reflow
The aim of this work is to study the role of intracoronary adrenaline administration as a preventive tool for no reflow in patients undergoing primary PCI.
- Trial name
- NCT06847568
- Testing
- Adrenaline
- Where
- Egypt
- Volunteers
- 1,000 people
- Sponsor
- Ain Shams University
Myocardial Infarction
THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction
The occurrence of no-reflow phenomenon after recanalization of the infarct related artery in acute myocardial infarction is described in up to 40% of cases.
- Trial name
- REOPEN-AMI (NCT00590070)
- Testing
- adenosine, nitroprusside
- Where
- Italy
- Volunteers
- 240 people
- Sponsor
- Catholic University of the Sacred Heart
ST-Segment Elevation Myocardial Infarction (STEMI), No-Reflow Phenomenon
Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.
- Conditions
- ST-Segment Elevation Myocardial Infarction (STEMI), No-Reflow Phenomenon, Coronary Slow Flow, Acute Myocardial Infarction
- Trial name
- AMPACT (NCT07536802)
- Testing
- Adenosine pre-medication, Standard care
- Where
- 2 sites in Pakistan
- Volunteers
- 1,148 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention
The EPIVER Randomized Controlled Trial
The trial aims to estimate the efficacy and safety of the intracoronary administration of adrenalin, verapamil, as well as their combination compared to standard treatment in patients with STEMI and refractory coronary no-reflow…
- Conditions
- ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention, No-Reflow Phenomenon
- Trial name
- EPIVER (NCT04573751)
- Testing
- Standard therapy, Epinephrine, Verapamil
- Where
- Russia
- Volunteers
- 104 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
ST-segment Elevation Myocardial Infarction
Association Between Plasma Melatonin and No-reflow
ST-segment elevation myocardial infarction (STEMI) is an acute manifestation of coronary heart disease, remaining a frequent cause of death.
- Trial name
- NCT03306303
- Volunteers
- 1,700 people
- Sponsor
- Chinese PLA General Hospital
No-Reflow Phenomenon
Alpha Lipoic Acid Effect on No-Reflow Phenomenon
Prospective, randomized, open-label, controlled clinical trial to evaluate the efficacy and tolerability of Alpha Lipoic Acid administration on oxidative stress, inflammatory markers, clinical outcome and occurrence of No-Reflow…
- Trial name
- NCT05360602
- Testing
- Alpha Lipoic Acid plus the standard care for post-PCI MI, The standard care for post-PCI MI
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
ST Elevation Myocardial Infarction, No-Reflow Phenomenon
Rivaroxaban for Slow Coronary Flow After PCI in STEMI
The goal of this clinical trial is to learn if drug Rivaroxaban works to improve slow flow in STEMI patients after PCI in adults. It will also learn about the safety of drug Rivaroxaban.
- Trial name
- NCT07195812
- Testing
- Dual Antiplatelet (DAPT) Therapy, Rivaroxaban
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
No Reflow Phenomenon, Reperfusion Injuries, Myocardial
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
Study Background \& Purpose: The no-reflow phenomenon is a significant complication occurring in patients with acute myocardial infarction who undergo percutaneous coronary intervention (PCI).
- Conditions
- No Reflow Phenomenon, Reperfusion Injuries, Myocardial, Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction
- Trial name
- NCT07898709
- Testing
- Empagliflozin (SGLT2i), dapagliflozin, Standard medical treatment
- Where
- 4 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Al-Azhar University
Myocardial Infarction
Nitroprusside for Prevention of no-Reflow in Primary Angioplasty
In patients admitted with acute myocardial infarction, there is a total occlusion of a coronary artery. Even after emergency catheterization and angioplasty, in some patients, the resumed blood flow is suboptimal and impacts on…
- Trial name
- NCT00128791
- Testing
- Nitroprusside
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Soroka University Medical Center
Acute Myocardial Infarction
Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy in Patients with Myocardial Infarction and No-reflow
Aim of the study is to examine the effects of glycoprotein IIb/IIIa inhibitors on reperfusion success assessed by cardiac magnetic resonance imaging in patients with myocardial infarction and angiographic evidence of no-reflow.
- Trial name
- REVERSE-FLOW (NCT02739711)
- Testing
- Glycoprotein IIb/IIIa inhibitors
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- University of Luebeck
ST-Elevation Myocardial Infarction (STEMI)
Reducing Slow/No-Reflow With Prophylactic High-Dose Intracoronary Adenosine Protocol in ST-Elevation Myocardial Infarction The REFLOW AMI Trial
The REFLOW AMI Trial aims to determine whether prophylactic high-dose intracoronary adenosine reduces slow-flow or no-reflow (SNR) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous…
- Trial name
- REFLOW AMI (NCT07898696)
- Testing
- Adenosine, Standard Treatment only
- Where
- 2 sites in Pakistan
- Volunteers
- 660 people
- Sponsor
- Prof Muzaffar Ali Zahidi